biostudies-literatureUnknown102Conte B<h4>Background</h4>Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools aiding in treatment decisions for TNBC. This study aims to assess the effectiveness of a B-cell/immunoglobulin signature (IGG) alone, or in combination with tumor burden, in predicting prognosis and treatment response in patients with TNBC.<h4>Methods</h4>Genomic and clinical data were retrieved from 7 cohorts: SCAN-B (N = 874), BrighTNess (n = 482), CALGB-40603 (n = 389), METABRIC (n = 267), TCGA (n = 118), GSE58812 (n = 107), GSE21653 (n = 67). IGG and a risk score integrating IGG with tumor/nodal staging (IGG-Clin) were assessed for event-free sEBioMedicine105043https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924177biostudies-literatureA 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.PMC10924177Prat AMartinez-Saez OParker JSFalato CPerou CMSchettini FSegui EGarcia-Fructuoso IVillacampa GStaaf JVivancos AConte BLorman-Carbo NAngelats LAdamo BFratini BVidal Losada MJHernandez ARSanfeliu EBraso-Maristany FChic NGomez-Bravo RVillagrasa PMarin-Aguilera MPascual TPare LfalseA 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.<h4>Background</h4>Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools aiding in treatment decisions for TNBC. This study aims to assess the effectiveness of a B-cell/immunoglobulin signature (IGG) alone, or in combination with tumor burden, in predicting prognosis and treatment response in patients with TNBC.<h4>Methods</h4>Genomic and clinical data were retrieved from 7 cohorts: SCAN-B (N = 874), BrighTNess (n = 482), CALGB-40603 (n = 389), METABRIC (n = 267), TCGA (n = 118), GSE58812 (n = 107), GSE21653 (n = 67). IGG and a risk score integrating IGG with tumor/nodal staging (IGG-Clin) were assessed for event-free s2024-01-01T00:00:00Z2024 Apr2026-05-29T12:28:04.861Z2024-11-09T19:15:58.109ZS-EPMC109241773844727510.1016/j.ebiom.2024.105043